|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.440 AUD | +2.95% |
|
-2.01% | -10.29% |
| 02-09 | Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6% | MT |
| 02-06 | ASX Biggest Losers | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Development of Cell Technology Platform for Commercialization | 7.46M | 10.21M | 7.5M | 5.9M | 17.2M | |||||
Total Assets | 745M | 662M | 669M | 669M | 785M | |||||
Interest Expense | -15.94M | -16.91M | -19.44M | -20.66M | -21.75M | |||||
Income Tax Expense | -819K | -239K | -212K | -191K | 330K | |||||
CAPEX | -1.65M | -232K | -264K | -271K | -680K | |||||
EBT | -99.63M | -91.59M | -82.1M | -88.15M | -102M | |||||
D&A | 4.26M | 4.38M | 4.11M | 4.67M | 6.4M | |||||
Net Income | -98.81M | -91.35M | -81.89M | -87.96M | -102M |
Geographical Revenue Distribution History
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
- Stock Market
- Equities
- MSB Stock
- Financials Mesoblast Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition